Global Fund Expands Push for Twice-Yearly HIV Drug as Access Race Intensifies

GENEVA — In a move that could signal a turning point in the decades-long fight against HIV, the Global Fund to Fight AIDS, Tuberculosis and Malaria announced this week an expanded commitment to accelerate access to lenacapavir, a breakthrough twice-yearly injectable for HIV prevention.

This expansion follows a landmark April 14, 2026, report detailing the organization’s efforts to ensure low- and middle-income countries (LMICs) are not left behind as this high-efficacy tool enters the market. Building on a 2025 procurement agreement with the drug’s manufacturer, Gilead Sciences, the Global Fund aims to reach 2 million people across supported nations over the next three years.

For the first time in the history of the HIV epidemic, a cutting-edge prevention product is slated to launch in developing nations simultaneously with high-income markets, potentially dismantling the “access gap” that has historically seen life-saving innovations take years, or even decades, to reach the world’s most vulnerable populations.

A Paradigm Shift in Prevention

The excitement surrounding lenacapavir stems from its delivery method: a subcutaneous injection administered just twice a year. For years, the gold standard for Pre-Exposure Prophylaxis (PrEP) has been a daily oral pill. While highly effective, daily adherence is a significant hurdle for many.

“Daily pills require a level of routine and privacy that many people simply do not have,” says Dr. Elena Rodriguez, an infectious disease specialist not affiliated with the recent trials. “A twice-yearly injection removes the burden of daily memory, the stigma of carrying pill bottles, and the logistical nightmare of frequent pharmacy visits.”

The Evidence: 100% Efficacy

The Global Fund’s push is backed by staggering data from two pivotal Phase 3 clinical trials:

• PURPOSE 1: Conducted among cisgender women in sub-Saharan Africa, the trial showed 100% efficacy. Out of thousands of participants, zero infections occurred among those receiving the lenacapavir injection.

• PURPOSE 2: This trial included cisgender men, transgender men, transgender women, and gender-diverse individuals across the globe. It reported a 96% reduction in HIV infections compared to background incidence, proving superior to the daily oral pill, Truvada.

Following these results, the World Health Organization (WHO) formally recommended lenacapavir in July 2025 as an additional PrEP option, providing the necessary policy “green light” for national health ministries to begin integration.

The Statistical Reality: Why Now?

Despite a 40% decline in new HIV infections since 2010, the global progress report for 2024 remains sobering. According to Global Fund data:

• 1.3 million new HIV infections occurred in 2024.

• The global target for 2025 is fewer than 370,000 infections, a goal the world is currently on track to miss.

• 630,000 people died of AIDS-related causes in 2024.

• Only 55% of the 1.4 million children living with HIV were on treatment last year.

“We are at a crossroads,” explains Marcus Thompson, a public health policy analyst. “We have the science to end the epidemic, but our delivery systems are lagging. Lenacapavir isn’t just a new drug; it’s a test of whether global health equity is a reality or just a slogan.”

Barriers to Global Rollout

While the clinical success of lenacapavir is undisputed, the “implementation gap” remains a formidable challenge. Experts point to several hurdles that must be cleared for the drug to make a dent in global infection rates:

1. Cost and Manufacturing

The price of lenacapavir in high-income markets is substantial. While Gilead has entered into non-exclusive royalty-free licensing agreements with generic manufacturers to supply LMICs, the speed at which these generics can be produced and distributed is critical.

2. Healthcare Infrastructure

Unlike a pill that can be picked up at a pharmacy, an injection requires a trained healthcare provider. This puts additional pressure on already strained health systems in sub-Saharan Africa and Southeast Asia.

3. “The Silent Gap” in Demographics

Data suggests that HIV still disproportionately affects specific groups. In 2024, adolescent girls and young women in sub-Saharan Africa remained at high risk, while “key populations”—including sex workers, people who inject drugs, and men who have sex with men—accounted for a significant portion of new infections globally.

Implications for the General Public

For the average reader, the rollout of lenacapavir represents a shift toward “discreet health.” For individuals in high-stigma environments, an injection every six months offers a level of privacy that daily pills cannot match.

However, medical professionals caution that lenacapavir is not a “silver bullet.”

“It is a prevention tool, not a cure,” says Dr. Rodriguez. “It does not protect against other sexually transmitted infections (STIs) like syphilis or gonorrhea. It must be part of a comprehensive sexual health plan that includes regular testing.”

The Road Ahead: From Lab to Life

The Global Fund’s expanded commitment signals that the focus has shifted from if the drug works to how it will be delivered. The organization is emphasizing “community-led delivery,” which involves bringing the injections to the people—via mobile clinics and community centers—rather than waiting for patients to travel long distances to major hospitals.

If successful, the synchronized launch of lenacapavir could rewrite the playbook for global health, ensuring that the most effective tools reach those with the highest need at the same time as those with the highest income.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

News & Statistical Sources

• Reuters. (2026, April 14). Global Fund expands commitment to improve access to HIV drug.